Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) Invested Capital: 2022-2025

Historic Invested Capital for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $411.4 million.

  • Centessa Pharmaceuticals' Invested Capital fell 17.58% to $411.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $411.4 million, marking a year-over-year decrease of 17.58%. This contributed to the annual value of $510.5 million for FY2024, which is 116.08% up from last year.
  • Per Centessa Pharmaceuticals' latest filing, its Invested Capital stood at $411.4 million for Q3 2025, which was down 9.48% from $454.5 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Invested Capital ranged from a high of $510.5 million in Q4 2024 and a low of $215.2 million during Q1 2024.
  • Its 3-year average for Invested Capital is $358.1 million, with a median of $293.3 million in 2023.
  • In the last 5 years, Centessa Pharmaceuticals' Invested Capital slumped by 38.92% in 2023 and then skyrocketed by 130.29% in 2025.
  • Centessa Pharmaceuticals' Invested Capital (Quarterly) stood at $336.2 million in 2022, then dropped by 29.72% to $236.2 million in 2023, then soared by 116.08% to $510.5 million in 2024, then declined by 17.58% to $411.4 million in 2025.
  • Its last three reported values are $411.4 million in Q3 2025, $454.5 million for Q2 2025, and $495.5 million during Q1 2025.